Premium
High dose calcitriol may reduce thrombosis in cancer patients
Author(s) -
Beer Tomasz M.,
Venner Peter M.,
Ryan Christopher W.,
Petrylak Daniel P.,
Chatta Gurkamal,
Dean Ruether J.,
Chi Kim N.,
Curd John G.,
DeLoughery Thomas G.
Publication year - 2006
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06322.x
Subject(s) - calcitriol , medicine , antithrombotic , docetaxel , thrombosis , placebo , calcitriol receptor , vitamin d and neurology , gastroenterology , vitamin k antagonist , cancer , oncology , atrial fibrillation , pathology , warfarin , alternative medicine
Summary The incidence of venous and arterial thrombosis in a placebo‐controlled randomised trial of DN‐101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN‐101 and 11 in placebo‐treated patients ( P = 0·01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti‐thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.